Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

TNFA (Tumor Necrosis Factor-Alpha)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

TNFA-L	Diffuse Large B Cell Lymphoma	TNFA-L	Diffuse Large B Cell Lymphoma	relmacabtagene autoleucel Sensitive: C3 – Early Trials relmacabtagene autoleucel Sensitive : C3	relmacabtagene autoleucel Sensitive: C3 – Early Trials relmacabtagene autoleucel Sensitive : C3
TNFA elevation	Cervical Cancer	TNFA elevation	Cervical Cancer	ipilimumab Resistant: C3 – Early Trials ipilimumab Resistant : C3	ipilimumab Resistant: C3 – Early Trials ipilimumab Resistant : C3
TNFA elevation	Non Small Cell Lung Cancer	TNFA elevation	Non Small Cell Lung Cancer	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
TNFA elevation	Non Small Cell Lung Cancer	TNFA elevation	Non Small Cell Lung Cancer	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
TNFA overexpression	Glioblastoma	TNFA overexpression	Glioblastoma	bevacizumab Resistant: C3 – Early Trials bevacizumab Resistant : C3	bevacizumab Resistant: C3 – Early Trials bevacizumab Resistant : C3
TNFA elevation	Small Cell Lung Cancer	TNFA elevation	Small Cell Lung Cancer	ipilimumab Resistant: C3 – Early Trials ipilimumab Resistant : C3	ipilimumab Resistant: C3 – Early Trials ipilimumab Resistant : C3
PD-L1 elevation + CXCL10 elevation + TNFA elevation	Melanoma	PD-L1 elevation + CXCL10 elevation + TNFA elevation	Melanoma	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3
TNFA-L	Cholangiocarcinoma	TNFA-L	Cholangiocarcinoma	bexmarilimab Sensitive: C3 – Early Trials bexmarilimab Sensitive : C3	bexmarilimab Sensitive: C3 – Early Trials bexmarilimab Sensitive : C3
TNFA-L	Melanoma	TNFA-L	Melanoma	bexmarilimab Sensitive: C3 – Early Trials bexmarilimab Sensitive : C3	bexmarilimab Sensitive: C3 – Early Trials bexmarilimab Sensitive : C3
TNFA-L	Gastric Cancer	TNFA-L	Gastric Cancer	bexmarilimab Sensitive: C3 – Early Trials bexmarilimab Sensitive : C3	bexmarilimab Sensitive: C3 – Early Trials bexmarilimab Sensitive : C3
TNFA elevation	Lung Cancer	TNFA elevation	Lung Cancer	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3
TNFA elevation	HER2 Positive Breast Cancer	TNFA elevation	HER2 Positive Breast Cancer	trastuzumab Sensitive: C3 – Early Trials trastuzumab Sensitive : C3	trastuzumab Sensitive: C3 – Early Trials trastuzumab Sensitive : C3